Lineage Cell Therapeutics Inc has 4 Schedule 13D or 13G filings on record since 2025-07-17. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Broadwood Partners, L.P. | 23.1% | 57,455,729 | SCHEDULE 13D/A, 2025-11-14 | 2025-11-12 |
| BlackRock, Inc. | 5.3% | 13,185,489 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Chernett Jorey | 5% | 11,445,003 | SCHEDULE 13G, 2025-09-26 | 2025-09-22 |
Purpose of Transaction (Item 4)
Broadwood Partners, L.P.
The Reporting Persons acquired their Shares for investment and are filing this Schedule 13D/A to report a decrease in their respective beneficial ownership percentages of the Shares as a result of the sale of 12,000,000 Shares by the Issuer to Janus Henderson Investors in a block transaction under the Issuer's at-the-market offering program as described in the Form 8-K filed with the Securities and Exchange Commission by the Issuer on November 12, 2025 (the "Form 8-K"). The foregoing is a summary of certain material terms of the Form 8-K. However, such summary is not, and does not purport to be, complete and is qualified in its entirety by reference to the full text of the Form 8-K, which has been filed as Exhibit B, and is incorporated herein by reference. Mr. Bradsher serves on the Board of Directors. Except as otherwise set forth below, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons reserve the right, at a later date, to effect one or more of such changes or transactions in the number of Shares they may be deemed to beneficially own in open-market or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable. The Reporting Persons have been and may continue to be in contact …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 1% | SCHEDULE 13G/A |
| 2025-09-26 | Chernett Jorey | 5% | SCHEDULE 13G |
| 2025-11-14 | Broadwood Partners, L.P. | 23.1% | SCHEDULE 13D/A |
| 2026-07-29 | BlackRock, Inc. | 5.3% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Lineage Cell Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.